Job Trends
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.
THE LATEST
Just a few weeks after celebrating the treatment of its 3,000th pet, national pet cancer care provider PetCure Oncology presented data suggesting that advanced radiation therapy delivered within PetCure-developed treatment protocols is leading to better survival outcomes than other treatment options for at least nine specific tumor types.
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
Last week was busy for clinical trial news. Here’s a look.
Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications.
It was a busy week for clinical trial announcements. Here’s a look.
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
It was another busy week for clinical trials. Here’s a look.
While Humira being the top-selling drug is on the decline due to increased competition and expiring patents, Keytruda is set to take the number-one position.
Collaboration will leverage Lantern’s proprietary AI platform and NCI’s platform to better predict patients’ tumor responses to specific drug classes and therapeutics